ClinicalTrials.gg

Program

Lu AF28996

A development code. Also written as “Lu AF28996 solution” and “Lu AF28996 capsule”.

Its studies are mostly in Parkinson Disease, led by H. Lundbeck.

Furthest: phase 2, since Mar 31, 20266 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
H. Lundbeck62 open or runningphase 2since Mar 31, 2026Jun 8, 2018May 31, 2027phase 1 · NCT07513441

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 8, 2018First study: phase 1 study in HealthyFirst studyNCT03565094 · 39 enrolled · Netherlands
  2. Feb 28, 2020Phase 1 study in Parkinson DiseaseNCT04291859 · 57 enrolled · United States, France, Germany and more
  3. Aug 16, 2023Phase 1 study in Parkinson DiseaseNCT06004180 · 6 enrolled · Japan
  4. Mar 22, 2024Phase 1 study in Healthy ParticipantsNCT06337110 · 8 enrolled · United Kingdom
  5. Mar 31, 2026Phase 2 study in Parkinson DiseasePhase 2 reachedNCT07514858 · 150 planned · United States, Czechia, Germany and more
  6. Mar 31, 2026Phase 1 study in Parkinson DiseaseNCT07513441 · 10 planned · China

Ahead

  1. May 31, 2027Primary completion: phase 1 study in Parkinson DiseaseNCT07513441
  2. Oct 3, 2028Primary completion: phase 2 study in Parkinson DiseaseNCT07514858

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07514858Parkinson Disease · United States, Czechia, Germany and more2RecruitingOct 3, 2028150
NCT07513441Parkinson Disease · China1RecruitingMay 31, 202710
NCT06337110Healthy Participants · United Kingdom1CompletedMay 11, 20248
NCT06004180Parkinson Disease · Japan1CompletedNov 21, 20236
NCT04291859Parkinson Disease · United States, France, Germany and more1CompletedOct 14, 202557
NCT03565094Healthy · Netherlands1CompletedAug 17, 201939

How it is read

Names in the registry

  • “Lu AF28996”, 5 entries
  • “Lu AF28996 solution”, 1 entry
  • “Lu AF28996 capsule”, 1 entry

Codes read as this program: LUAF28996.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.